Insurance most likely wont cover Ozempic for sleep apnea, since that specific drug isnt FDA-approved for it, Wojeck says
Retatrutide needs additional TRIUMPH trial results throughout 2026 before submitting for FDA approval in late 2026 or early 2027, with approval expected in late 2027 and launch in early 2028
It works on three different receptors
GLP-1 receptor agonist medications mimic these effects pharmacologically, producing several mechanisms that contribute to weight loss: Reduced appetite and food intake by activating satiety signaling in the brain, these medications meaningfully reduce hunger and food preoccupation for most patients Slower gastric emptying food remains in the stomach longer, prolonging the feeling of fullness after meals Improved insulin sensitivity better glucose regulation reduces post-meal energy crashes that often drive cravings Lower preference for high-calorie foods many patients report shifts in food preferences toward lighter, less calorie-dense options Tirzepatide adds a second mechanism by also activating GIP (glucose-dependent insulinotropic polypeptide) receptors, which is believed to contribute to its greater weight loss effect compared to semaglutide alone
1,2 Practical ways to manage side effects Eat smaller meals Eat slowly and mindfully Stop when you feel full, not when the plate is empty Avoid meals higher in fat in the two hours after your injection Include lean protein at each meal (chicken, fish, beans, eggs, tofu, Greek yoghurt) Stay hydrated and sip water throughout the day Dont lie down after meals
Move at least an inch away from your last spot each time, or switch to a new zone entirely
